Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries. Pfizer announced in August that the World Health Organization granted prequalification status to Prevenar 13, a condition for the drug to be used by United Nations agencies, including UNICEF. Pfizer Vaccines President Mark Swindell spoke with PharmAsia News following the WHO announcement to discuss the company's vaccine strategy in emerging markets.
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC075879

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel